Treatment with the senolytics dasatinib/quercetin reduces SARS-CoV-2-related mortality in mice.

ABSTRACT: The enormous societal impact of the ongoing COVID-19 pandemic has been particularly harsh for some social groups, such as the elderly. Recently, it has been suggested that senescent cells could play a central role in pathogenesis by exacerbating the pro-inflammatory immune response against SARS-CoV-2. Therefore, the selective clearance of senescent cells by senolytic drugs may be useful as a therapy to ameliorate the symptoms of COVID-19 in some cases. Using the established COVID-19 murine model K18-hACE2, we demonstrated that a combination of the senolytics dasatinib and quercetin (D/Q) significantly reduced SARS-CoV-2-related mortality, delayed its onset, and reduced the number of other clinical symptoms. The increase in senescent markers that we detected in the lungs in response to SARS

SUBMITTER: Pastor-Fernandez A 

PROVIDER: S-EPMC10014049 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature